<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">11109184</PMID>
        <DateCompleted>
            <Year>2001</Year>
            <Month>01</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>02</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0020-7314</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>30</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2000</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of health services : planning, administration, evaluation</Title>
                <ISOAbbreviation>Int J Health Serv</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmaceutical expenditure in Spain: cost and control.</ArticleTitle>
            <Pagination>
                <MedlinePgn>597-616</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In recent years, the Spanish government has been battling to keep pharmaceutical expenditures under control. Its measures include control of prices, introduction of a &quot;negative list&quot; of drugs no longer reimbursed, increased cost-sharing, and introduction of overall budgets for pharmaceutical expenditures. Although the average prices of old pharmaceutical products declined by 39 percent over the last 15 years and consumption in value increased by only 10 percent, real pharmaceutical expenditures in Spain increased by 264 percent over that period. The main reason for the continuing rise in these expenditures and the failure of cost-containment measures is the introduction of new, more expensive drugs, which often fail to offer any real therapeutic advantages over products already on the market. This situation is exacerbated by a lack of effective demand-side measures such as budgets for doctors and lack of a generics market.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lopez Bastida</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>London School of Economics and Political Science, England.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mossialos</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Int J Health Serv</MedlineTA>
            <NlmUniqueID>1305035</NlmUniqueID>
            <ISSNLinking>0020-7314</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016568">Drugs, Generic</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D003363" MajorTopicYN="N">Cost Control</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017047" MajorTopicYN="N">Cost Sharing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016527" MajorTopicYN="N">Drug Costs</DescriptorName>
                <QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
                <QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016568" MajorTopicYN="N">Drugs, Generic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005569" MajorTopicYN="N">Formularies as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005102" MajorTopicYN="N">Health Expenditures</DescriptorName>
                <QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
                <QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006301" MajorTopicYN="N">Health Services Needs and Demand</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007349" MajorTopicYN="N">Insurance, Health, Reimbursement</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007356" MajorTopicYN="N">Insurance, Pharmaceutical Services</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010593" MajorTopicYN="N">Pharmaceutical Services</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
                <QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013222" MajorTopicYN="N">State Medicine</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>2</Month>
                <Day>28</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11109184</ArticleId>
            <ArticleId IdType="doi">10.2190/YL3J-QK9B-0NMQ-KMVK</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>